keyboard_arrow_up

Personalized Medicine in Oncology Partnering Terms and Agreements

Reportstack has announced a new market research publication on Personalized Medicine in Oncology Partnering Terms and Agreements which provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.
 
The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
 
The report provides an orientation of personalized medicine in oncology dealmaking and business activities. It also provides an overview of the trends in personalized medicine in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in personalized medicine in oncology partnering. The chapter also includes examples case studies of recent deals in personalized medicine in oncology partnering.
                             
The report also provides a review of the leading personalized medicine in oncology deals since 2007. Deals are listed by headline value signed by all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
It also provides a comprehensive and detailed review of personalized medicine in oncology partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.
 
The report also includes numerous tables and figures that illustrate the trends and activities in personalized medicine in oncology partnering and dealmaking since 2007.
                                                  
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of personalized medicine in oncology technologies and products.
 
Report scope
 
Personalized Medicine in Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.
 
Personalized Medicine in Oncology Partnering Terms and Agreements includes:
 
Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2007
Analysis of personalized medicine in oncology deal structure
Case studies of real-life personalized medicine in oncology deals
Access to over 600 personalized medicine in oncology deals
The leading personalized medicine in oncology deals by value since 2007
Most active personalized medicine in oncology dealmakers since 2007
The leading personalized medicine in oncology partnering resources
 
In Personalized Medicine in Oncology Partnering Terms and Agreements , the available contracts are listed by:
 
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific technology target
 
Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

key benefits:
 
In-depth understanding of personalized medicine in oncology deal trends since 2007
Analysis of the structure of personalized medicine in oncology agreements with numerous real life case studies
Comprehensive access to over 600 personalized medicine in oncology deals entered into by the world’s biopharma companies
Detailed access to actual personalized medicine in oncology contracts enter into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a personalized medicine in oncology agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies.

The companies mentioned in the report are Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Merck KGaA, Novartis, Pfizer, Roche, Sanofi, Servier, Teva. 

To view the table of contents and know more details please visit Personalized Medicine in Oncology Partnering Terms and Agreements report.